{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040049","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.078381+00:00","generated_at":"2026-06-08T06:59:45.211150+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Co-Diagnostics Q3 revenue $2.5M, net loss $6.0M; receives $9.0M Gates Foundation grant","bullets":["Revenue $2.5M, down from $5.1M in prior year due to declining COVID-19 test demand.","Net loss of $6.0M ($0.20/sh) vs $1.4M loss ($0.04/sh) in prior year.","Received $9.0M grant from Bill & Melinda Gates Foundation for TB test development on Co-Dx PCR platform.","Expects EUA submission to FDA for Co-Dx PCR Pro platform and COVID-19 assay by year-end 2023.","Cash and securities $63.4M as of Sept 30, 2023; repurchased 149,041 shares at $1.12 avg."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040049","json":"https://secwatch.observer/filing/0001493152-23-040049.json","markdown":"https://secwatch.observer/filing/0001493152-23-040049.md","text":"https://secwatch.observer/filing/0001493152-23-040049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315223040049/0001493152-23-040049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315223040049/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:59:45.211150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"da29a177aa9634623b61ea9fe9add1613e4c0d47","claim":"Co-Diagnostics, Inc. reported quarter ended September 30, 2023 results: revenue $2.5 million, net income $6.0 million, EPS $0.20 per fully diluted share.","evidence_excerpt":"the development of molecular diagnostic tests, today announced financial results for the quarter ended September 30, 2023. Third Quarter 2023 Financial Results: ● Revenue of $2.5 million, down from $5.1 million during the prior year primarily due to the anticipated decline in global demand for COVID-19 tests. Grant revenue totaled $2.3 million while product","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315223040049/0001493152-23-040049-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2023"},{"label":"Revenue","value":"$2.5 million"},{"label":"Net income","value":"$6.0 million"},{"label":"EPS","value":"$0.20 per fully diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}